Establishment Labs (NASDAQ:ESTA – Get Free Report) and Bone Biologics (NASDAQ:BBLG – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Establishment Labs and Bone Biologics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Establishment Labs | 0 | 1 | 3 | 1 | 3.00 |
Bone Biologics | 0 | 0 | 0 | 0 | 0.00 |
Establishment Labs currently has a consensus target price of $60.60, indicating a potential upside of 43.81%. Given Establishment Labs’ stronger consensus rating and higher possible upside, analysts plainly believe Establishment Labs is more favorable than Bone Biologics.
Risk & Volatility
Profitability
This table compares Establishment Labs and Bone Biologics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Establishment Labs | -46.13% | -184.55% | -24.81% |
Bone Biologics | N/A | -124.71% | -111.64% |
Institutional & Insider Ownership
72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 11.4% of Establishment Labs shares are held by company insiders. Comparatively, 7.5% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Establishment Labs and Bone Biologics”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Establishment Labs | $153.07 million | 7.71 | -$78.50 million | ($2.58) | -16.33 |
Bone Biologics | N/A | N/A | -$8.95 million | N/A | N/A |
Bone Biologics has lower revenue, but higher earnings than Establishment Labs.
Summary
Establishment Labs beats Bone Biologics on 9 of the 12 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.